Hantz Financial Services
ZVRA icon

Hantz Financial Services’s Zevra Therapeutics ZVRA Stock Holding History

Hantz Financial Services’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-18
Closed – – 2006
2024
Q4 		$0 Hold
18
– – ﹤0.01% 1228
2024
Q3 		$0 Hold
18
– – ﹤0.01% 1199
2024
Q2 		$0 Hold
18
– – ﹤0.01% 1298
2024
Q1 		$0 Hold
18
– – ﹤0.01% 1310
2023
Q4 		$0 Hold
18
– – ﹤0.01% 1242
2023
Q3 		$0 Hold
18
– – ﹤0.01% 1199
2023
Q2 		$0 Hold
18
– – ﹤0.01% 1190
2023
Q1 		$0 Hold
18
– – ﹤0.01% 1215
2022
Q4 		$0 Hold
18
– – ﹤0.01% 1171
2022
Q3 		$0 Hold
18
– – ﹤0.01% 1150
2022
Q2 		$0 Hold
18
– – ﹤0.01% 1125
2022
Q1 		$0 Buy
+18
New +$115 ﹤0.01% 1130

Other funds holding ZVRA

Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Hantz Financial Services's ZVRA Position: Q1 2025 in Review

Hantz Financial Services sold out of Zevra Therapeutics (ZVRA) in Q1 2025, closing a stake of 18 shares.

Hantz Financial Services first reported a position in ZVRA in Q1 2022 and held it in 12 quarters. The position peaked at $0 in Q4 2024. 110 funds tracked by Wall St. Rank hold ZVRA as of Q1 2025.

  • Hantz Financial Services reported no remaining Zevra Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Hantz Financial Services sold 18 Zevra Therapeutics shares in Q1 2025.
  • Hantz Financial Services first reported a position in Zevra Therapeutics in Q1 2022 and held it in 12 quarters.
  • Hantz Financial Services's Zevra Therapeutics position peaked at $0 in Q4 2024.
  • 110 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2025.

Based on Hantz Financial Services's 13F filing for Q1 2025, filed 12 May 2025.